Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
NCT04622566
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
26
Enrollment
OTHER
Sponsor class
Conditions
Mucosal Melanoma
Neoadjuvant Treatment
Interventions
DRUG:
Lenvatinib, Pembrolizumab
Sponsor
Peking University Cancer Hospital & Institute